Regeneron (REGN) and Sanofi (SNY) announced that the European Commission has approved Dupixent for the treatment of moderate-to-severe chronic spontaneous urticaria in adult and adolescent patients 12 years and above with inadequate response to histamine-1 antihistamines and who are naive to anti-immunoglobulin E therapy for CSU. Eligible patients can use Dupixent as a first-line targeted treatment option.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN: